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Abstract
Early stopping of clinical trials in favour of a new treatment creates
ethical and scientific difficulties, which are different from those
associated with early stopping due to toxicity or futility. Two major
breast cancer trials have recently taken such a decision, and the
problem is relevant for several ongoing trials. Here we argue that
such a decision should be taken with the utmost gravity and should
be based on a clear overall clinical benefit for the new treatment,
and not as an automatic response to crossing a predefined
threshold. Predefined rules can be used to trigger a debate within
the Independent Data Monitoring and Safety Committee (IDMC)
about early stopping, but the IDMC should retain the responsibility
of assessing overall clinical benefit in making its recommendation.
Introduction
The conduct of clinical trials requires a careful and meticulous
consideration of the rights of the individual to autonomy and
self-determination on one hand and, on the other, the needs
of society to learn which treatment is most effective for a
particular disease. This tension is present from the very
outset, when patients are asked to consent to randomization,
and continues throughout the trial, as early events accrue and
results for other related studies are reported. Independent
Data Monitoring and Safety Committees (IDMCs) are now de
rigueur for all trials, and are charged with regularly reviewing
this balance and protecting the interests of patients.
A key tenet of this whole activity is the concept of uncertainty.
This principle underpins the credibility of all clinical trials, and
considerable experience and maturity are required for a full
understanding of its ramifications. In simplest terms this
principle holds that randomization is appropriate for an
individual patient if the clinician has substantial uncertainty as
to which of two (or more) treatments is likely to provide
greatest clinical benefit to him or her. In most cases this is not
a precise knife-edge balancing of risks and benefits, but a
determination of whether the patient fits in a large grey area
where there is uncertainty.
In the past, differences in approaches to treatment led to
separate schools of thought as to how best to treat a
disease. At best, only indirect, often unbalanced,
comparisons were available for determining the superiority of
one treatment over another (or even any effectiveness beyond
a placebo effect). About 50 years ago, enlightened physicians
realized the weakness of this approach; they agreed to
suspend their personal prejudices temporarily and subject
their preferred treatment to a head-on comparison with a
treatment championed by other doctors. The randomized
clinical trial was born, and with it came all the ethical and
social dilemmas associated with suspending personal
prejudices and with temporarily accepting uncertainty until
clear evidence emerges for a clinical benefit for one or
another treatment. We still struggle with this concept and
with recent attempts to more formally provide procedures for
evaluating uncertainty that have led to unease among
ourselves and others.
It seems to us that the uncertainty principle requires that clear
evidence of clinical benefit of a new treatment should be
obtained before a trial is stopped with a recommendation to
accept a new treatment. There is a clear asymmetry here, in
that stopping a trial early in favour of a new treatment is
different from stopping a trial with a negative
recommendation. The primary role of the IDMC is to protect
the safety of the patients. Any unexpected or excessive
toxicity of a new treatment requires prompt action – either to
halt the trial temporarily while a remedy is sought, or to
abandon it altogether. Additionally, early stopping when the
efficacy of a new treatment seems worse, or even when it
becomes clear that it is unlikely to be significantly better than
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standard treatment (so-called futility analyses) is also an
important consideration for the IDMC.
The HABITS (‘hormonal replacement therapy after breast
cancer – is it safe?’) trial is a good example of this. It was
expected that the use of hormone replacement therapy would
have minimal impact on recurrence in breast cancer patients,
but early results showed a threefold increase [1]. Although
some individuals question the knock-on effect of early
stopping on other ongoing trials in which no excess was
seen, safety considerations dictate a cautious approach in
this instance.
It is clear that the threshold for action here should be lower
than early stopping for success. Especially for futility
analyses, it is important to consider whether the trial can
usefully contribute to an overview that could provide a
definitive answer, but when the patient population is limited or
there are no similar ongoing trials a decision to stop a trial in
favour of standard treatment (or no treatment) can, in our
view, be appropriate even when there is overall clinical
uncertainty. A good example of this was the combination arm
in the ATAC (arimidex, tamoxifen alone or in combination)
trial. It was dropped when the combination did not seem to
be materially different from tamoxifen, but the use of
anastrozole alone was superior [2].
However, the threshold for action when a new treatment looks
promising should be much higher. Of particular concern to us
has been the early stopping of trials when early endpoints
(such as disease-free survival or time to recurrence) are
positive. This has precluded any opportunity of clearly
establishing overall benefit. The expansion of randomized
clinical trials into areas requiring prolonged treatment of
patients with a relatively good prognosis has exacerbated this
problem, because many patients are still on active treatment
when these interim analyses are done, and the time to
definitive outcome (death or distant recurrence) is long.
Paradoxically, the early stopping of trials with apparently
successful outcomes can delay full acceptance of the
treatment. When uncertainty still persists in a substantial
segment of the medical community, the trial has not achieved
its primary goal, and the main aim of the trial remains
unanswered. There seems to be a trend towards giving IDMCs
inflexible rules as to when they must stop trials, and this is
taking precedence over their judgement about whether there is
a clear clinical benefit associated with the new treatment.
What is to be done about this?
It seems to us that there are two actions that would help to
rectify the situation.
First, IDMCs should be given back the duty of making
judgements about the clinical benefit of any differences seen
in early endpoints. Stopping rules are useful for setting
triggers that would initiate this activity, but IDMCs should
then review safety, toxicity and other potential long-term
evidence before coming to a recommendation about
irrevocably abandoning a trial.
Second, when early indicators are positive but it is felt that
clinical benefit has not been achieved, procedures for
reporting these results in a way that does not require
unblinding should be developed. This will require informing
patients of the interim results, indicating that further follow-up
is necessary to obtain definitive results, and seeking re-
consent to continue in this trial. This has been successfully
achieved in both the first International Breast Cancer
Intervention Study (IBIS-I) [3] and ATAC trials [4] and is very
much in the spirit of treating patients as partners in research,
rather than simply as subjects exposed to new treatments.
This approach is particularly important for trials of prolonged
treatment in patients with a good prognosis (for example
adjuvant hormone and prevention trials) in which interim
results are likely to be available at a time when many patients
still have a substantial period of active treatment ahead of
them.
Such a partnership requires developing a different
relationship with patients at the time of diagnosis and keeping
them informed about the progress of the trial. It would be
helpful if the consent form signed at the outset embodied
these principles. Ideally, awareness of this partnership
approach to clinical trials should be publicized and debated
quite generally so that patients are aware of and comfortable
with it before disease is apparent.
Could this approach have been employed in
the trials that were stopped early?
For the National Surgical Adjuvant Breast and Bowel Project
P-1 (NSABP-P1) tamoxifen prevention trial [5], the IBIS-I
experience suggests that with an appropriate advance
information and understanding, continuation would have been
well tolerated and even valued.
The ATAC trial also demonstrates the ability to report positive
results for new treatment and yet not unblind the patients.
Very few patients on tamoxifen or anastrozole have requested
unblinding. Should this have been done for the MA17 trial of
extended treatment with letrozole after tamoxifen [6]? The
original question of 5 years of treatment after 5 years of
tamoxifen asked in that trial has not been answered, although
it is now being used as the standard against which to
compare 5 years of letrozole against 10 years of letrozole
after initial treatment with 5 years of tamoxifen. No mortality
benefit is yet apparent and it is unclear whether the present
difference in recurrence will translate into a real difference.
The recent report [7] of a significant mortality benefit in node-
positive patients also noted a non-significant detriment in
node-negative patients, with a non-significant overall mortality
benefit. What are we to make of this? The implications of183
unblinding would be a switch of placebo patients to letrozole
after a 29-month median gap. Is this beneficial? Given these
uncertainties would it not have been better to report the
result but give the patients the opportunity to remain on
blinded treatment if they wished?
Similar questions arose in the Intergroup Exemestane Study
trial [8], which compared 5 years of tamoxifen with switching
to exemestane after 2 to 3 years of tamoxifen. A highly
significant difference in favour of switching was reported, but
most patients had completed treatment or would do so within
a year, so the results were published and patients were
informed. However, the blinding and treatment schedules
were maintained and randomized treatment was continued in
consenting patients. This is very important and should allow a
long-term assessment of the effect on mortality to be
determined.
Similar questions will now arise in the BIG 1-98 trial [9] in
which an early benefit for letrozole over tamoxifen has been
reported. The situation is somewhat different here, because
more evidence is available from other trials on the subject,
and after the initial 2 years of treatment women may also
switch treatment or continue for a further 3 years. The
positive interim results from three adjuvant trials of
trastuzumab (Herceptin) recently announced at ASCO [10]
will also require careful consideration of these issues,
although significant mortality benefits were also seen here.
These issues will always be a matter of judgement and
differing opinion, but we feel that the IDMC’s role must
include an assessment of clinical benefit in addition to looking
at the primary endpoint, and it is in everyone’s interest that
the decision to abandon a trial in favour of the new treatment
is taken with the utmost gravity. When early indicators are
strongly positive, but an effect on definitive endpoints has not
yet been established, we need to find a way to announce
these early findings without damaging the chances of
obtaining the conclusive results that the trial set out to
provide. Perhaps we should involve the patients more in this
process and provide them with the opportunity to remain in
the trial until clinical benefit is clearly established.
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